Gregory Grunberg

NOCD is the #1 telehealth provider for the treatment of obsessive-compulsive disorder (OCD). OCD is one of the most severe, prevalent, and misunderstood mental health conditions. NOCD creates access to online therapy for people with OCD through our innovative telehealth platform. In the NOCD app, members can quickly access and schedule live, face-to-face video therapy sessions with our national network of licensed therapists that specialize in Exposure and Response Prevention Therapy (ERP) - considered the "gold standard" in OCD treatment. In between sessions, patients have access to 24/7 support through NOCD’s self-help tools and peer communities. At NOCD, we help people reclaim their lives with clinically proven OCD treatment, by removing barriers to OCD care, and reducing the stigma associated with OCD.

At On Belay, we believe that fixing healthcare starts with primary care. That’s why we are supporting primary care teams in delivering the best possible care for all their patients, while also ensuring their own well-being and sustainability. A strong and vibrant practice means better patient health and experience.

Cortica is a leading provider of ABA and other therapies for children with autism, with services available in-center, in-home, and via telehealth. Cortica’s personalized, whole-child approach integrates diagnostic services, medical services for autism’s co-occurring conditions, developmental therapies including occupational therapy and speech-language therapy, and individual and family counseling, all under one roof. For more information, please visit corticacare.com.

Cohere Health is a clinical intelligence company that provides intelligent prior authorization as a springboard to better quality outcomes by aligning physicians and health plans on evidence-based care paths for the patients entire care journey. Coheres intelligent prior authorization solutions reduce administrative expenses while improving patient outcomes. The company is a winner of the TripleTree iAward and has been named to both Fierce Healthcares Fierce 15 and CB Insights Digital Health 150 lists. Coheres investors include Flare Capital Partners, Define Ventures, Deerfield, Polaris Partners, and Longitude Capital.

The leading provider of outcomes-driven care for individuals and communities living with chronic conditions.

WelbeHealth provides full-service care to help seniors age well at home and in their community, often at no cost. Services include medical, coordination, home care, dental, transport, physical therapy, prescriptions, social activities and meals. Founded by a seasoned group of physician entrepreneurs, our leadership team hails from leading payer and provider organizations such as GoHealth Urgent Care, BAYADA Home Health, AirStrip Technologies, Evolent Health, and On Lok. With funding from leading venture investors, were looking for team members who are inspired to help us deliver on our mission of unlocking the full potential of the most vulnerable seniors. Our colleagues are energized by working in diverse groups toward our shared purpose, are eager to drive groundbreaking innovations, and have the courage to care for our participants with empathy and love.

Weaving along Hawaii's Na Pali Coast is the famous, breathtaking Kalalau trail. This trail is not only notable for its strenuous path and terrain that is difficult to traverse, but also known for its unsurpassed beauty. Kalalau was early inspiration for us, today representing our innovative spirit and deep commitment to advancing the treatment of eye diseases. Kala is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye. Kala’s biologics-based investigational therapies utilize Kala’s proprietary Mesenchymal Stem Cell Secretome (MSC-S) platform. Kala’s lead product candidate, KPI-012, is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, which has received orphan drug designation from the U.S. Food and Drug Administration. Kala is also targeting KPI-012 for the treatment of Partial Limbal Stem Cell Deficiency and ocular manifestations of moderate-to-severe Sjögren's and plans to initiate preclinical studies to evaluate the utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. For more information on Kala, please visit www.kalarx.com.

Weaving along Hawaii's Na Pali Coast is the famous, breathtaking Kalalau trail. This trail is not only notable for its strenuous path and terrain that is difficult to traverse, but also known for its unsurpassed beauty. Kalalau was early inspiration for us, today representing our innovative spirit and deep commitment to advancing the treatment of eye diseases. Kala is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye. Kala’s biologics-based investigational therapies utilize Kala’s proprietary Mesenchymal Stem Cell Secretome (MSC-S) platform. Kala’s lead product candidate, KPI-012, is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, which has received orphan drug designation from the U.S. Food and Drug Administration. Kala is also targeting KPI-012 for the treatment of Partial Limbal Stem Cell Deficiency and ocular manifestations of moderate-to-severe Sjögren's and plans to initiate preclinical studies to evaluate the utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. For more information on Kala, please visit www.kalarx.com.

SARcode Bioscience Inc. is a biotechnology company based out of 1000 Marina Boulevard Suite 250, Brisbane, California, United States.

Temasek is a global investment company headquartered in Singapore, with a net portfolio value of S$518 billion (US$401b, €350b, £304b, RMB2.77t) as at 31 March 2026. Our Purpose “So Every Generation Prospers” guides us to make a difference for today’s and future generations. We seek to build a resilient and forward-looking portfolio that will deliver good sustainable returns over the long term. We have 13 offices in 9 countries around the world: Beijing, Hanoi, Mumbai, Shanghai, Shenzhen, and Singapore in Asia; and Brussels, London, Mexico City, New York, Paris, San Francisco, and Washington, DC outside Asia. For more information on Temasek, please visit www.temasek.com.sg For Temasek Review 2026, please visit www.temasekreview.com.sg For Sustainability Report 2026, please visit www.temasek.com.sg/SR2026 To keep up with news and insights from Temasek follow us on X: Temasek (@Temasek) on X Facebook: www.facebook.com/temasekholdings YouTube: www.youtube.com/user/temasekdigital Instagram: www.instagram.com/temasekseen Telegram: https://t.me/temasekholdings WeChat: temasek_digital Tiktok: https://www.tiktok.com/@temasek Temasek does not give investment advice, gather personal information or ask for payment from followers.

NOCD is the #1 telehealth provider for the treatment of obsessive-compulsive disorder (OCD). OCD is one of the most severe, prevalent, and misunderstood mental health conditions. NOCD creates access to online therapy for people with OCD through our innovative telehealth platform. In the NOCD app, members can quickly access and schedule live, face-to-face video therapy sessions with our national network of licensed therapists that specialize in Exposure and Response Prevention Therapy (ERP) - considered the "gold standard" in OCD treatment. In between sessions, patients have access to 24/7 support through NOCD’s self-help tools and peer communities. At NOCD, we help people reclaim their lives with clinically proven OCD treatment, by removing barriers to OCD care, and reducing the stigma associated with OCD.

At On Belay, we believe that fixing healthcare starts with primary care. That’s why we are supporting primary care teams in delivering the best possible care for all their patients, while also ensuring their own well-being and sustainability. A strong and vibrant practice means better patient health and experience.

Cortica is a leading provider of ABA and other therapies for children with autism, with services available in-center, in-home, and via telehealth. Cortica’s personalized, whole-child approach integrates diagnostic services, medical services for autism’s co-occurring conditions, developmental therapies including occupational therapy and speech-language therapy, and individual and family counseling, all under one roof. For more information, please visit corticacare.com.

Cohere Health is a clinical intelligence company that provides intelligent prior authorization as a springboard to better quality outcomes by aligning physicians and health plans on evidence-based care paths for the patients entire care journey. Coheres intelligent prior authorization solutions reduce administrative expenses while improving patient outcomes. The company is a winner of the TripleTree iAward and has been named to both Fierce Healthcares Fierce 15 and CB Insights Digital Health 150 lists. Coheres investors include Flare Capital Partners, Define Ventures, Deerfield, Polaris Partners, and Longitude Capital.